Darolutamide and Lisinopril: Safety Profile
Key Safety Considerations
- Darolutamide is associated with increased hypertension rates compared to placebo, with hypertension occurring more frequently in the darolutamide group (13.7% vs 9.2% with placebo) 1, 2
- The American Journal of Kidney Diseases recommends ensuring baseline blood pressure is controlled on current lisinopril regimen before initiating darolutamide 3
Clinical Management Algorithm
- The American Journal of Kidney Diseases suggests documenting baseline blood pressure readings and current antihypertensive medications 3
- The Journal of the National Comprehensive Cancer Network recommends monitoring blood pressure closely, particularly during the first 3 months of therapy when hypertension risk may be highest 1, 2
- The Journal of Clinical Oncology recommends checking blood pressure at each clinic visit (recommended every 4-8 weeks initially) 4
- The American Journal of Kidney Diseases recommends being prepared to uptitrate lisinopril or add additional antihypertensive agents if blood pressure control deteriorates 3
- The American Journal of Kidney Diseases suggests targeting systolic blood pressure <130 mm Hg for patients with comorbidities 3
Important Caveats
- The American Journal of Kidney Diseases states that the combination of darolutamide and lisinopril is not contraindicated, but requires vigilant monitoring rather than avoidance 3
- The Journal of Clinical Oncology recommends counseling patients about the potential for worsening hypertension and the need for adherence to both cancer therapy and antihypertensive medications 4